Infinity Pharmaceuticals, Inc. (INFI) Rises A lot Today, Is Now One of The Best Performer

March 14, 2018 - By Ellis Scott

Investors sentiment decreased to 0.47 in Q3 2017. Its down 0.16, from 0.63 in 2017Q2. It dropped, as 15 investors sold Infinity Pharmaceuticals, Inc. shares while 23 reduced holdings. 6 funds opened positions while 12 raised stakes. 27.30 million shares or 18.05% less from 33.31 million shares in 2017Q2 were reported.
Jpmorgan Chase And holds 118,435 shares. Nationwide Fund Advisors reported 49,500 shares. D E Shaw & Inc owns 421,544 shares or 0% of their US portfolio. Amer Financial Group Inc invested 0.01% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). State Street holds 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) for 67,405 shares. Bvf Inc Il invested 1.33% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Royal Bank Of Canada reported 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Financial Bank Of America De has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Virtu Limited Liability Corporation invested 0% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Quantitative Investment Mngmt Ltd holds 46,400 shares. Dimensional Fund Advsr L P accumulated 0% or 90,953 shares. Jacobs Levy Equity Management reported 99,527 shares. Ameriprise Fin Incorporated accumulated 0% or 79,010 shares. 2.21M were reported by Orbimed Advsr Limited Liability Com. Geode Capital Mngmt Limited Co accumulated 266,503 shares or 0% of the stock.

Since October 3, 2017, it had 1 buy, and 1 insider sale for $1.99 million activity. Shares for $13,890 were sold by Perkins Adelene Q.

The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is a huge mover today! The stock increased 8.91% or $0.22 during the last trading session, reaching $2.69. About 1.14 million shares traded or 41.93% up from the average. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has declined 60.96% since March 14, 2017 and is downtrending. It has underperformed by 77.66% the S&P500.
The move comes after 7 months positive chart setup for the $136.41 million company. It was reported on Mar, 14 by We have $2.77 PT which if reached, will make NASDAQ:INFI worth $4.09M more.

Analysts await Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) to report earnings on March, 15 after the close. They expect $-0.27 EPS, up 41.30 % or $0.19 from last year’s $-0.46 per share. After $-0.14 actual EPS reported by Infinity Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 92.86 % negative EPS growth.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Ratings Coverage

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 2 have Buy rating, 0 Sell and 7 Hold. Therefore 22% are positive. Infinity Pharmaceutical had 16 analyst reports since August 7, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of INFI in report on Friday, August 7 with “Outperform” rating. On Wednesday, June 15 the stock rating was downgraded by Jefferies to “Hold”. The firm earned “Overweight” rating on Monday, September 21 by Morgan Stanley. JMP Securities downgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on Tuesday, June 14 to “Market Perform” rating. The firm earned “Equal-Weight” rating on Wednesday, June 15 by Morgan Stanley. The stock has “Outperform” rating by Wells Fargo on Thursday, October 12. The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has “Market Perform” rating given on Wednesday, June 15 by William Blair. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. The stock has “Market Perform” rating by Wells Fargo on Wednesday, June 15. The company was downgraded on Tuesday, March 22 by Wedbush.

Another recent and important Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) news was published by which published an article titled: “Infinity Pharmaceuticals Announces Additions to Board of Directors and …” on March 08, 2018.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $136.41 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: